Daily ergothioneine supplementation for people with kidney failure on dialysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

People with kidney failure who receive hemodialysis or peritoneal dialysis will be enrolled and given either a daily ergothioneine supplement or a matching placebo. Blood ergothioneine levels will be measured over the treatment period to see whether supplementation replenishes circulating levels. Participants who recently had a blood transfusion or who already take ergothioneine-containing supplements are excluded. The intervention is administered at a single site in Palo Alto, and safety and tolerability will also be monitored.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion Criteria:

* blood transfusion within 90 days
* taking supplements which contain ergothioneine

Where it's running

• Veterans Affairs Palo Alto
  Palo Alto, California, United States Recruiting

Study contacts

• Principal investigator: Tammy Sirich, MD — Stanford University
• Study coordinator: Tammy Sirich, MD
• Email: tsirich@stanford.edu
• Phone: 650-493-5000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Canagliflozin to improve ultrafiltration and reduce peritoneal fibrosis in people on peritoneal dialysis

  We will test whether taking canagliflozin reduces glucose absorption by the peritoneal membrane and improves ultrafiltration in people on peritoneal dialysis.

  Recruiting Phase 2 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT06913647

• Adding urea to the final dialysis fluid

  This test tries adding urea to the dialysis fluid for adults with advanced kidney failure who have very high blood urea and need rapid lowering of potassium or correction of severe acidosis.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT06366230

• SelfWrap-Assisted Arteriovenous Fistulas for Chronic Kidney Disease

  This study is testing if a new wrap called SelfWrap can make it safer and more effective for people with chronic kidney disease to have a new arteriovenous fistula created.

  Recruiting at 28 sites VenoStent · Bullhead City, Arizona and 27 other locations · NCT06001827

• Registering patients on peritoneal dialysis in China

  This study is trying to gather information from patients on peritoneal dialysis in China to see how they are doing and improve their care.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT02989298

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• Remote monitoring in dialysis: comparing RPM-APD, manual PD, and maintenance HD

  This study tests how well three dialysis approaches work for adults with ESRD starting dialysis in China, using real-world data from routine care.

  Recruiting Vantive Health LLC · Beijing, Beijing Municipality and 19 other locations · NCT07781124

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.